1. Biomarkers, Assays, and Therapies for Alzheimer Disease.

    Clinical Chemistry 61(7):903 (2015) PMID 26015517

  2. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

    Brain 138(Pt 4):1036 (2015) PMID 25688083

    Prior studies indicate psychiatric symptoms such as depression, apathy and anxiety are risk factors for or prodromal symptoms of incipient Alzheimer's disease. The study of persons at 50% risk for inheriting autosomal dominant Alzheimer's disease mutations allows characterization of these sympto...
  3. Building a roadmap for developing combination therapies for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(3):327 (2015) PMID 25708309

    Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treatin...
  4. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

    JAMA Neurology 72(3):287 (2015) PMID 25622185

    In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
  5. Building a roadmap for developing combination therapies for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(3):327 (2015) PMID 25708309

    Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treatin...
  6. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

    JAMA Neurology 72(3):287 (2015) PMID 25622185

    In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
  7. Charting a path toward combination therapy for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(1):107 (2015) PMID 25540951

    It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from in...
  8. Charting a path toward combination therapy for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(1):107 (2015) PMID 25540951

    It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from in...
  9. Charting a path toward combination therapy for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(1):107 (2015) PMID 25540951

    It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from in...
  10. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  11. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  12. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  13. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  14. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  15. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  16. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  17. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  18. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  19. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  20. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....